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Abstract We take a functional genomics approach to congenital heart disease mechanism. We used
DamID to establish a robust set of target genes for NKX2-5 wild type and disease associated NKX2-5
mutations to model loss-of-function in gene regulatory networks. NKX2-5 mutants, including those with
a crippled homeodomain, bound hundreds of targets including NKX2-5 wild type targets and a unique
set of "off-targets", and retained partial functionality. NKXΔHD, which lacks the homeodomain
completely, could heterodimerize with NKX2-5 wild type and its cofactors, including E26 transformation-
specific (ETS) family members, through a tyrosine-rich homophilic interaction domain (YRD). Off-targets
of NKX2-5 mutants, but not those of an NKX2-5 YRD mutant, showed overrepresentation of ETS binding
sites and were occupied by ETS proteins, as determined by DamID. Analysis of kernel transcription factor
and ETS targets show that ETS proteins are highly embedded within the cardiac gene regulatory
network. Our study reveals binding and activities of NKX2-5 mutations on WT target and off-targets,
guided by interactions with their normal cardiac and general cofactors, and suggest a novel type of gain-
of-function in congenital heart disease.
DOI: 10.7554/eLife.06942.001
Introduction
The mammalian heart is a highly modified muscular vessel whose lineage programmes are governed
by conserved gene regulatory networks (GRNs) (Davidson and Erwin, 2006). The cardiomyocyte
GRN is controlled by lineage-restricted transcription factors (TFs), which interact to form a recursively
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wired sub-network termed the cardiac ‘kernel’ (Davidson and Erwin, 2006). Kernel TFs, such as
NKX2-5, GATA4, TBX5/20, and serum response factor (SRF), show regionally restricted expression
and act as selector proteins that help define developmental and organ-specific territories. A well-
studied kernel TF is NKX2-5, a member of the NK-2 homeodomain (HD) factor subclass that plays an
early role in development of hearts and heart-like organs of diverse species (Elliott et al., 2010). Loss
of Nkx2-5 in mice leads to arrested heart morphogenesis due to blocked progenitor growth, defective
chamber and conduction system development, and a deranged GRN (Prall et al., 2007). In humans,
NKX2-5 is one of the most commonly mutated single genes in congenital heart disease (CHD), with
dominant alleles causing atrial septal defect and atrioventricular conduction block most commonly,
and a host of more severe defects at lower penetrance (Elliott et al., 2010). Many CHD-causing
NKX2-5 mutations are located within the conserved HD (Figure 1A), which serves as both a sequence-
specific DNA-binding domain and protein-binding interface for interactions with other kernel TFs
(Elliott et al., 2010). It is widely assumed that CHD is caused by haploinsufficiency and an inability of
mutant proteins to recognise target genes. However, we know little about disease causation at the
genome level, and in fact, most CHD mutations lie outside of the HD (Figure 1A), often in conserved
domains with largely unknown functions.
Here, we take a functional genomics approach to understanding the mechanism of NKX2-5 CHD at
the chromatin level. We applied the technique of DNA adenine methyltransferase identification
(DamID) (Vogel et al., 2006) to identify target genes of NKX2-5 wild type and NKX2-5 mutant
proteins mimicking those found in patients with CHD. While binding of severe NKX2-5 mutants to
targets was compromised, they nonetheless associated with hundreds of targets, including many
normally bound by NKX2-5 wild type, and could regulate a subset of these in cellular assays. We
demonstrate that severe NKX2-5 mutant proteins retained an ability to interact with NKX2-5 wild type
and other cardiac TFs via a novel tyrosine-rich protein:protein interface in NKX2-5 that lies outside of
the HD. NKX2-5 mutant proteins also bound hundreds of ‘off-targets’ not bound by NKX2-5 wild type,
eLife digest Many genes working within large gene networks influence the development of
heart muscle cells in humans and other animals. The activity of these genes is controlled in part by
proteins called transcription factors, which bind to DNA and act as molecular switches. One
transcription factor that is particularly important for the development of heart muscle cells is called
NKX2-5.
Mice lacking NKX2-5 have abnormal hearts and many humans who are born with congenital heart
disease carry mutations in the gene that encodes this protein. Many of these mutations alter
a section of the protein called the homeodomain, and therefore interfere with the ability of NKX2-5
to bind to DNA or associate with other important cardiac proteins called cofactors. However, it is not
clear how such mutations alter the behaviour of NKX2-5 across all of its targets.
Bouveret et al. have now used a technique called ‘DNA adenine methyltransferase identification’
to study how NKX2-5 interacts with other proteins and DNA. The experiments found that, as
expected, the mutant NKX2-5 proteins were unable to associate with many of the usual gene and
protein targets of normal NKX2-5. However, the mutant proteins were still able to bind to some of
their usual targets, plus many other targets that the normal NKX2-5 protein was not able to bind to.
A particular NKX2-5 mutant protein that the experiments analysed was missing the entire
homeodomain, yet it was still able to associate with the normal NKX2-5 protein and bind to cofactors
that help NKX2-5 to find its usual targets. This finding led Bouveret et al. to discover the role of
a section of the NKX2-5 protein called the tyrosine-rich domain, which in the absence of the
homeodomain can direct interactions of NKX2-5 with itself and its cofactors.
Bouveret et al.’s findings suggest that protein cofactors of NKX2-5 help mutant NKX2-5 proteins
retain some of their normal activities, but also direct the mutant proteins to abnormal gene targets,
which could contribute to congenital heart disease. The next steps are to carry out experiments in
animals to confirm these findings, and to understand the activities of mutant NKX2-5 and other
mutant transcription factors across the whole genome. This could lead to new therapeutic
approaches to treat congenital heart disease and other conditions.
DOI: 10.7554/eLife.06942.002
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Figure 1. DNA adenine methyltransferase identification (DamID) identifies a robust set of NKX2-5 targets in HL-1 cardiomyocytes. (A) Structure of the
human NKX2-5 protein (TN, tinman domain; NK2SD, NK-2 specific domain; YRD, tyrosine-rich domain). Bars and arrows indicate missense and termination
mutations associated with congenital heart disease (CHD), respectively. (B) Top over-represented motifs discovered de novo in NKX2-5 peaks using
Trawler orWeeder. NKX2-5, GATA, and Nuclear Factor 1 (NF1) binding motifs deposited in TRANSFAC are shown. (C) Distribution of NKX2-5, GATA, and
NF1 binding sequences in NKX2-5 peaks. (D) Yeast-two-hybrid assay. NKX2-5 and NF1 proteins were fused to Gal4-activation and DNA-binding domains,
respectively. Positive signs (+) show interaction as growth on selective medium from three independent experiments. (E) Normalized median expression
of NKX2-5-target genes in 91 murine cell types (data collected from BioGPS). Tissues with the highest median expressions are shown in colour, including
heart (red). (F) Expression of NKX2-5 target genes and random genes in HL-1 cells. Data collected from (Mace et al., 2009).
DOI: 10.7554/eLife.06942.003
The following figure supplements are available for figure 1:
Figure supplement 1. DamID validation in HL-1 cardiomyocytes.
DOI: 10.7554/eLife.06942.004
Figure supplement 2. Expression of PGK-GFP control 24 hr post-transduction of HL-1 cells transduced with lentivirus (LV).
DOI: 10.7554/eLife.06942.005
Figure supplement 3. PCR-amplified methylated fragments of HL-1 genomic DNA 40 hr post-transduction with Dam alone and Dam-NKX2-5.
DOI: 10.7554/eLife.06942.006
Figure supplement 4. False discovery rate of Dam/TF fusion protein binding peaks as determined using CisGenome/TileMapv2 with moving
average ≥ 3.5.
DOI: 10.7554/eLife.06942.007
Figure supplement 5. Chromatin immunoprecipitation (ChIP)-PCR validation of NKX2-5 WT target peakes determined by DamID.
DOI: 10.7554/eLife.06942.008
Figure supplement 6. NKX2-5 binds the NKE but not the NF1-like motif.
DOI: 10.7554/eLife.06942.009
Figure 1. continued on next page
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via altered DNA-recognition or via interactions with previously unrecognised cofactors. These
cofactors, which include members of the ETS family, are embedded in the cardiac GRN, indicating
a broad role for ubiquitous TFs in cardiac network logic and mechanism of CHD.
Results
DamID identification of NKX2-5 WT targets
DamID is a sensitive enzymatic method developed to identify protein:DNA interactions (van Steensel
and Henikoff, 2000; van Steensel et al., 2001). It is complementary to chromatin immunoprecip-
itation (ChIP) but avoids artifacts associated with chromatin crosslinking and poor-quality ChIP
antibodies (Waldminghaus and Skarstad, 2010; Teytelman et al., 2013). DamID involves creation of
a fusion between a chromatin-binding protein of interest and Escherichia coli DNA adenine
methyltransferase (Dam). When expressed, Dam fusions bind to DNA, whereby Dam locally
methylates adenine within its target sites (5′GATC3′). Target DNA can then be released using DpnI,
a nuclease specific for the methylated Dam site, and analysed on arrays (Vogel et al., 2006).
Here, we used DamID in HL-1 cells, which resemble atrial cardiomyocytes, to profile NKX2-5 WT
and mutants that mimic those found in CHD (Claycomb et al., 1998). Mouse Nkx2-5 cDNAs were
cloned into a lentiviral Dam vector carrying heat shock and ponasterone A-inducible promoters
(Vogel et al., 2006). Only N-terminal Dam fusions (Dam-NKX2-5) were analysed because C-terminal
fusions were sterically compromised (data not shown). Ponasterone A induction after viral
transduction of HEK Ecr-293 cells confirmed nuclear localisation and the correct size of fusions
(Figure 1—figure supplement 1). Transduction of HL-1 cells was efficient (∼97%; Figure 1—figure
supplement 2). DamID fusions were expressed from the uninduced heat shock protein 68 promoter at
very low levels (undetectable by western blotting), which was sufficient for Dam enzymatic activity on
chromatin (Figure 1—figure supplement 3) but avoided skewing of the network. DamID is
dependent on the density of DpnI sites (5′GATC3′), which occur on average every 260 bp in the
mouse genome, as in the fly genome (van Steensel and Henikoff, 2000). After DpnI digestion of
virus-transduced HL-1 cell DNA, PCR-amplification lead to fragments of ∼200-2000 bp
(Figure 1—figure supplement 3). We determined that of all perfect NKX2-5 high-affinity binding
sites (NKE; 5′AAGTG3′) in the mouse genome, 90% had a DpnI site within 1 kb upstream and
downstream (median of ∼289 bp), suggesting that DamID captures the vast majority of NKX2-5 direct
targets.
Methylated genomic fragments were hybridised to Affymetrix Mouse promoter microarrays in
biological triplicate. These microarrays represent 7.3% of the mouse genome, and we estimate from
published NKX2-5 ChIPseq data that they would capture 20–30% of all NKX2-5 peaks (He et al.,
2011; van den Boogaard et al., 2012). DamID peaks were determined using CisGenome after
subtraction of signal obtained from cells expressing Dam alone (Ji et al., 2008) (see Supplementary
file 1, and UCSC genome browser http://genome.ucsc.edu/cgi-bin/hgTracks?db=mm9&type=
bed&hgt.customText=ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE44nnn/GSE44902/suppl/GSE44902_
DamID.bed.gz [Kent et al., 2002]).
For NKX2-5 WT, we identified 1524 peaks, which displayed low-false discovery rates (<0.08;
Figure 1—figure supplement 4). ChIP-PCR confirmed NKX2-5 occupancy over NKX2-5 DamID peaks
for 10 out of 11 targets tested, while DamID-negative regions were not occupied (Figure 1—figure
supplement 5). De novo motif discovery using Weeder or Trawler (Pavesi and Pesole, 2006; Haudry
et al., 2010) revealed that the top 3 over-represented motifs were 5′AAGTG3′, identical to the NKE;
Figure 1. Continued
Figure supplement 7. Identification of NKX2-5, SRF, and ELK1/4 target genes in HL-1 cells.
DOI: 10.7554/eLife.06942.010
Figure supplement 8. Nuclear localisation of NKX2-5 and histone modifications in HL-1 cardiomyocyte nuclei.
DOI: 10.7554/eLife.06942.011
Figure supplement 9. Proportional Venn diagram showing the overlapping binding peaks between NKX2-5 determined by DamID (this study) or
ChIP-seq (He et al., 2011 ) and (van den Boogaard et al., 2012).
DOI: 10.7554/eLife.06942.012
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5′GATAA3′, identical to the GATA-binding motif; and 5′TGCCAA3′, similar to the binding motif of
Nuclear Factor 1 (NF1) (Figure 1B). After counting of their exact sequences, the NKE was present in
79% of NKX2-5 peaks, with half of these bearing over 2 and up to 12 NKEs. The GATA- and NF1-
binding motifs were present in 59% and 36% of peaks, respectively (Figure 1C). These results suggest
that the majority of NKX2-5 WT targets are directly bound via the NKE and also support the
combinatorial action of NKX2-5 with GATA factors on many targets (Durocher et al., 1997; He et al.,
2011). NKX2-5 did not bind directly to the NF1-like site in vitro (Figure 1—figure supplement 6),
suggesting that NKX2-5 could act in combination with NF1 in HL-1 cells. Using a yeast two-hybrid
(Y2H) assay, we showed that NKX2-5 interacted with NF1-B1 and NF1-B3 but not NF1-A or NF1-X
(Figure 1D), as for the related family members NKX2-1 and NF1 in lung (Bachurski et al., 2003). This
suggests that NF1-B1/3 regulate a subset of target genes in combination with NKX2-5 in
cardiomyocytes.
Using GREAT (McLean et al., 2010), NKX2-5 peaks were assigned to 1490 unique genes, including
previously identified NKX2-5 target genes (Figure 1—figure supplement 7). NKX2-5 also bound its
own promoter, potentially reflecting auto-regulation (Prall et al., 2007). Gene Ontology (GO) analysis
of DamID NKX2-5 targets showed that the most enriched biological processes were heart
development and muscle contraction (Supplementary file 1), attesting to the specificity of DamID.
The most represented words amongst the top 50 GO terms, were muscle, development, regulation,
cardiac, and cell. Other enriched processes included cytoskeleton organisation and related terms, and
metabolic GO terms such as regulation of cellular carbohydrate catabolic process, regulation of
glycolysis, and regulation of generation of precursor metabolites and energy, indicating that NKX2-5
exerts high-level network control over metabolic processes.
In silico analysis using the BioGPS repository of 91 tissue transcriptomes revealed that the median
expression level of NKX2-5 target genes was highest in adult hearts (Figure 1E). Transcriptome data
for HL-1 cells (Mace et al., 2009) showed that NKX2-5 targets were strongly skewed towards higher
expression values compared to genes randomly selected from the array, although some genes were
expressed at lower levels (Figure 1F). We note from immunofluorescence studies that the most
intense NKX2-5 staining co-localised in speckle-like nuclear foci with active histone marks H3K9Ac and
H3K4me3, but not with repressive mark H3K27me3 (Figure 1—figure supplement 8).
Probing the mechanisms of CHD using DamID
Having established a robust NKX2-5 WT target list, we set out to probe the mechanisms of CHD by
identifying the genome-wide targets of NKX2-5 mutant proteins. We first constructed N-terminal Dam
fusions for the human CHD mutation NKX2-5Y191C (Benson et al., 1999), which disrupts tyrosine 54 of
the HD, necessary for the unique binding site specificity of the NK-2 homeoprotein sub-class to the NKE
(Figure 2A). In vitro, NKX2-5Y191C dimerises normally with co-factors but shows 80-fold reduced binding
to the NKE (Kasahara et al., 2000; Kasahara and Benson, 2004). We also created NKX2-5ΔHD, in which
the HD was deleted and replaced by a glycine-linker. We anticipated that NKX2-5ΔHD would be
functionally dead, since the HD has been shown to serve as both DNA-binding domain and interface for
homo- and hetero-dimerisation (Elliott et al., 2010). However, we were interested in testing whether the
presence of other conserved domains in NKX2-5 and often mutated in NKX2-5-related CHD (Figure 2A)
could confer any functionality to the NKX2-5 mutants. Both mutants were stable (Figure 1—figure
supplements 1, 6) and, as anticipated, did not bind efficiently to the NKE of the known target Nppa
(natriuretic peptide precursor A) (Durocher et al., 1996) in vitro (Figure 1—figure supplement 6).
Surprisingly, in HL-1 cells, both NKX2-5Y191C and NKX2-5ΔHD associated with a large number of
loci (1149 and 792 peaks, respectively; Figure 2B; Supplementary file 1) with low false discovery
rates (Figure 1—figure supplement 4). Even though NKX2-5Y191C cannot bind DNA, the most over-
represented motifs were 5′AAGTGT3′ (NKE), 5′GATAA3′ (GATA), and 5′TGCCAA3′ (NF1-like),
exactly as for NKX2-5 WT fusion (Supplementary file 1). NKX2-5Y191C peaks also showed over-
representation of the motif 5′TAATC3′, which is similar to the binding sites of many non-NK-2 class
HD proteins, including HOX proteins, as well as that of NK-2 proteins that lack HD tyrosine 54, such as
NKX1-2 (Berger et al., 2008). NK-2 class proteins which do carry Y54 in their HDs, including NKX2-5,
also bind to this HOX-like site, albeit with a 10-fold-reduced affinity compared to that of the NKE
(Chen and Schwartz, 1995). For NKX2-5ΔHD peaks, there were many over-represented motifs,
although none resembled known cardiac TF-binding sites (Supplementary file 1).
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Figure 2. NKX2-5 mutants bind to hundreds of targets in HL-1 cells. (A) Structure of NKX2-5Y191C and NKX2-5ΔHD
mutant proteins (‘G’ indicates a Glycine linker). (B) Overlapping binding peaks between NKX2-5 WT and mutants.
Proportional Venn diagrams show peaks unique to WT NKX2-5 (A sets); common to WT and mutant proteins (B sets);
Figure 2. continued on next page
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The ability of NKX2-5Y191C and NKX2-5ΔHD to bind a large number of targets was unexpected.
Hence we sought to confirm using an independent approach that these mutants could interact with
chromatin in vivo. We employed photoactivatable fluorescence correlation spectroscopy (paFCS)
(Kaur et al., 2013), measuring the diffusion dynamics of NKX2-5 WT and mutants within individual
HL-1 nuclei (Figure 2—figure supplement 1A). Expression vectors encoding NKX2-5 proteins fused
to photoactivatable GFP (paGFP) were introduced by transfection. As for other TFs, NKX2-5 WT
showed a biphasic behaviour, with a freely diffusing fraction similar to paGFP (adjusted for molecular
mass) and a slower, chromatin-interacting fraction. NKX2-5 WT displayed slower diffusion (dwell time
τDslow = 121 ms) than that mutants (NKX2-5Y191C: τDslow = 64 ms; NKX2-5ΔHD: τDslow = 11 ms),
which diffused more slowly than paGFP alone (Figure 2C, Figure 2—figure supplement 1B-D). This
confirmed that NKX2-5Y191C and NKX2-5ΔHD physically interact with chromatin (Kaur et al., 2013)
and suggests that a gradation in chromatin tethering correlates with the apparent severity of the
NKX2-5 mutation (WT>Y191C>ΔHD>paGFP).
NKX2-5 mutant targets overlap partially with NKX2-5 WT targets
We compared NKX2-5 WT and mutant peaks and adopted a simple nomenclature (A, B, and C) for
peak subsets, where A is bound by NKX2-5 WT only, B is bound by both WT and a mutant, and C is
bound only by a mutant (Figure 2B). In both comparisons, the A sets predominated (81% and 53% of
NKX2-5 WT peaks in the NKX2-5 WT/ΔHD and NKX2-5 WT/Y191C comparisons, respectively), and
their most enriched motif determined de novo was the NKE (Figure 2D), demonstrating that, as
anticipated, NKX2-5 mutants failed to bind to most WT targets, including Nppa. Therefore, the HD
mutations result in a severe loss of function. However, a high proportion of mutant peaks overlapped
with NKX2-5 WT peaks (B sets; 36% of 792 NKX2-5ΔHD peaks and 63% of 1149 NKX2-5Y191C peaks).
To investigate the A- and B-set logic further, we used Clover (Frith et al., 2004) to calculate the
enrichment of known TF motifs present in TRANSFAC (BIOBASE) and JASPAR databases (Bryne
et al., 2008) in A and B sets separately (Figure 2—figure supplement 2). The NKE was significantly
enriched in both A and B sets, showing that A and B sets contain direct NKX2-5 targets. A- and B-sets
also exhibited distinct enrichment signatures for many known TF motifs, for example, those for cardiac
kernel TFs GATA4, HAND1, and MEF2 were only enriched in the B-set of the NKX2-5 WT/ΔHD
comparison. Thus, both mutants can bind a subset of direct WT targets despite crippled DNA binding.
This likely occurs via dimerisation with endogenous NKX2-5 WT and/or its cofactors (see below and
[Kasahara et al., 2000]). Indeed, for NKX2-5ΔHD, which completely lacks a DNA-binding domain, our
data suggest that a protein:protein interface within NKX2-5 that is distinct from the HD can guide the
mutant protein to NKX2-5 WT targets.
At a GO term level, the A- and B-sets were also distinct (Figure 2—figure supplement 3;
Supplementary file 1). For the Y191C/ΔHD comparison, the A-set showed virtually no enrichment
for GO terms and the B-set was primarily enriched in functions related to heart development. For the
WT/ΔHD comparison, the overlap in GO terms between the A-set and B-set was also very small, with
the A-set being primarily enriched in terms related to cellular functions, such as actin filament
Figure 2. Continued
unique to mutant proteins (C sets). (C) Representative autocorrelation function (ACF) curves and fits for NKX2-5 WT
and mutant proteins measured by photoactivatable fluorescence correlation spectroscopy (paFCS) in HL-1 cells.
(D) Top over-represented motifs discovered de novo using Weeder in A-, B- and C-target sets of NKX2-5 WT and
mutant comparisons.
DOI: 10.7554/eLife.06942.013
The following figure supplements are available for figure 2:
Figure supplement 1. (A) Image showing paGFP-NKX2-5 and histone 2B-RFP fluorescence in a single HL-1 nucleus
with fluorescence correlation spectroscopy (FCS) measurement performed at the crosshair point.
DOI: 10.7554/eLife.06942.014
Figure supplement 2. Enrichment of known motifs in NKX2-5 peak subsets.
DOI: 10.7554/eLife.06942.015
Figure supplement 3. Enrichment of GO terms in NKX2-5 target subsets.
DOI: 10.7554/eLife.06942.016
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organisation and transcription, and the B-set being enriched in functions related to heart and blood
vessel development. This suggests that NKX2-5 mutants preferentially associate with genes involved
in cardiac related processes.
Functionality of NKX2-5 mutants
Based on the DamID and pFCA data above showing an association between NKX2-5 mutants and
chromatin, we tested the functionality of NKX2-5 mutants in vivo, selecting Inhibitor of DNA binding
3 (Id3) as a B set gene bound by NKX2-5 WT, Y191C, and ΔHD for detailed analysis (Figure 3A).
Id3 encodes a bHLH factor that represses cardiogenic differentiation in heart progenitor cells and is
down-regulated as progenitors differentiate and levels of NKX2-5 increase (Ding et al., 2006).
Using qRT-PCR, we confirmed previous microarray data that Id3 is up-regulated in Nkx2-5 null mouse
mutant hearts, similar to other cardiac progenitor genes (Prall et al., 2007), whereas Nppa, a known
directly activated NKX2-5 target, is down-regulated (Figure 3—figure supplement 1). The Id3
downstream region, when cloned into a minimal promoter/luciferase vector in antisense orientation
and transfected into HEK 293 cells, stimulated transcription ∼18-fold. Activity was stimulated a
further fourfold by SRF (Figure 3—figure supplement 1), which DamID indicated also bound to this
region (Figure 3A and below). NKX2-5 WT, Y191C, and ΔHD repressed both the basal and SRF-
stimulated activity (Figure 3B), suggesting that NKX2-5 mutants retain some WT functionality as
repressors of Id3.
To test functionality of NKX2-5 mutants in a developmental context, we generated mouse embryonic
stem (ES) cells in which expression of exogenous NKX2-5 WT or mutants could be conditionally induced
by doxycycline (dox)-dependent activation of a ubiquitous promoter (Bondue et al., 2008, 2011).
Following induction of cardiogenesis, NKX2-5 WT, Y191C, and ΔHD proteins were activated in most or
all embryoid body (EB) cells with dox at day 4, 1 day before, endogenous NKX2-5 appears in a minority
of cells within cardiogenic clusters (Figure 3C). Comparable levels of NKX2-5 WT and mutant mRNAs
and protein were detected 1–2 days post-induction (Figure 3—figure supplement 2). Induced NKX2-5
WT strongly repressed formation of FLK1+/PDGFRα+ multipotent cardiovascular progenitors at day 5
(Figure 3D), and of cardiomyocytes (cTNT+) and endothelial cells (CD31+) at day 8 (Figure 3E-F).
Repression of cardiac lineages by NKX2-5 in ES cells is consistent with its demonstrated early role as
a negative feedback regulator of cardiac induction and second heart field gene expression (Prall et al.,
2007), and as an inhibitor of reprogramming of cardiac fibroblasts to a cardiomyocyte fate (Ieda et al.,
2010). NKX25ΔHD was nuclear in only 15% of cells at day 6 (likely due to deletion of the nuclear
localisation signal within the HD; Figure 3—figure supplement 2C) and had no effect on cardiac or
endothelial cell differentiation (Figure 3E-F) and so was not considered further. NKX2-5Y191C was
nuclear and, while showing no effects on myocardial progenitors or endothelial cells in three
independent experiments, showed a trend towards inhibition of cardiomyocyte numbers at day 8
(∼44%; p = 0.079), suggesting that it also retained some repressive activity in this assay.
To gain deeper insights into the underlying effects, we therefore measured alterations in gene
expression in the ES cell lines at day 5–6 in three independent experiments, testing a selection of A
and B-set genes derived from the NKX2-5WT:Y191C comparison. The majority of both A (8/12) and B
(12/13) set genes tested were modulated >1.5 fold by NKX2-5 WT (total 20/25), providing strong
evidence that DamID selects NKX2-5 WT developmental targets. Within B-set genes, most were
repressed by NKX2-5 WT, consistent with the repression of cardiogenesis by NKX2-5 WT at early
stages of cardiac lineage specification (Prall et al., 2007). A subset of A and B set genes was also
regulated by NKX2-5Y191C (A-set: 3/12; B-set: 4/13; Figure 3G), despite no change in early myocardial
progenitors in the NKX2-5Y191C line, with regulation by Y191C being in the same direction as for
NKX2-5 WT. As examples, Actc1, Nkx2-5, Hand2, and Gata4 were repressed by both NKX2-5 WT and
NKX2-5Y191C, whileNppa and Tbx3were activated by both. These data show that while NKX2-5Y191C
loses its ability to bind and regulate most normal NKX2-5 targets, it nonetheless retains some of the
regulatory capabilities of NKX2-5 WT.
Novel interface for NKX2-5 dimerisation
Our results showing that the NKE is enriched in both B-sets suggest that NKX2-5 mutants can bind
targets by dimerising with NKX2-5 WT. While dimerisation to NKX2-5 WT has been demonstrated for
NKX2-5Y191C (Kasahara and Benson, 2004), it was surprising for NKX2-5ΔHD because the HD has
Bouveret et al. eLife 2015;4:e06942. DOI: 10.7554/eLife.06942 8 of 30
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Figure 3. NKX2-5 mutant proteins retained partial functionality. (A) UCSC Genome Browser screen shot
showing DamID transcription factor (TF) association in HL-1 cells with Inhibitor of DNA binding 3 (Id3).
(B) Normalised Rluc activity in HEK 293 cells transfected with NKX2-5 and serum response factor (SRF).
Id3 DR was in the antisense orientation. p-values were calculated relative to controls (** p < 0.01;
Figure 3. continued on next page
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been previously described as being essential for NKX2-5 homodimerisation (Elliott et al., 2010).
Transfected NKX2-5ΔHD was largely cytoplasmic in CV-1 cells (Figure 4A), which lack endogenous
NKX2-5. This is likely a consequence of the deletion of the NKX2-5 nuclear localisation signal located
in the amino terminus of the HD (Kasahara and Izumo, 1999). However, NKX2-5ΔHD became nuclear
when co-expressed with NKX2-5 WT, which itself was nuclear when transfected alone (Figure 4A).
Cofactors GATA4, TBX5, and TBX20, which have been reported to bind NKX2-5 WT via the HD also
induced nuclear translocation of NKX2-5ΔHD (Figure 4—figure supplement 1). In HL-1 cells, which
express endogenous NKX2-5 and its cardiac cofactors, transfected NKX2-5ΔHD was predominantly
nuclear although some protein was present in the cytoplasm (Figure 4B). These data demonstrate
that NKX2-5 WT and its cofactors are able to carry NKX2-5ΔHD into the nucleus via an unknown
protein:protein interaction not involving the HD.
To demonstrate the presence of this interface independently, we used a Renilla luciferase protein
fragment complementation assay (Rluc-PCA) (Stefan et al., 2007) with a weakened Cytomegalovirus
(CMV) promoter to avoid protein aggregation. This assay confirmed NKX2-5 WT homo-dimerisation,
hetero-dimerisation between NKX2-5 WT and NKX2-5ΔHD, and homo-dimerisation of NKX2-5ΔHD
(Figure 4C). It also confirmed interactions between NKX2-5ΔHD and GATA4, TBX5, and TBX20
(Figure 4—figure supplement 2). We further employed processed spectral Fluorescence Resonance
Energy Transfer (psFRET) (Chen et al., 2007), detecting robust Fluorescence Resonance Energy
Transfer (FRET) from NKX2-5 WT/WT homodimers or WT/ΔHD heterodimers in the nucleus and
from ΔHD/ΔHD homodimers in the cytoplasm (Figure 4D–E), the latter result demonstrating that
dimerisation was independent of chromatin binding.
To define the dimerisation domain, we used the Y2H assay (Figure 4F). Full-length NKX2-5
interacted with peptides carrying the NKX2-5 HD (aa137-196) or C-terminal region (aa198-318)
but not with the N-terminal region (aa1-135). The C-terminal peptide could also interact with
itself. The conserved tyrosine-rich domain (YRD), present within the C-terminal region (Figure 1A),
was essential for the interaction between full-length NKX2-5 and the C-terminus, being blocked by
the NKX2-5YRDY−A mutation in which all 9 tyrosines of the YRD are mutated to alanine. We have
previously shown that NKX2-5YRDY−A does not affect DNA binding, although it has a strong dominant-
negative activity leading to lethal CHD-like phenotypes in high-level heterozygous ES cell chimaeras,
and when placed over the null allele creates a phenocopy of NKX2-5 loss-of-function (Elliott et al.,
2006). Mutation of other conserved domains within the C-terminus (NK2-specific domain; Nkx2-5
box) had no affect on the interaction (Figure 4F). While the NKX2-5 HD is known to be a homophilic
interaction domain (Elliott et al., 2010), our Y2H data identify the YRD as a novel dimerisation interface
within NKX2-5. This YRD-dependent interaction, demonstrated in both yeast and mammalian
cells, provides the mechanism for heterodimerisation of NKX2-5 WT with NKX2-5ΔHD, as well as
homodimerisation of NKX2-5ΔHD.
Figure 3. Continued
*** p < 0.001; **** p < 0.0001; ns = not significant) or SRF alone (†† p < 0.01; ††† p < 0.001; †††† p < 0.0001).
The quantity of vector is given in ng. (C) Schematic representation of ‘Materials and methods’ for the
generation of embryonic stem (ES) cell lines for inducible expression of NKX2-5 WT and mutants. Cardiac
differentiation was initiated in embryoid bodies (EBs), followed by induction of cardiogenesis differentiation
(from day 4) on plates. (D) FACS quantification of PDGFRa/FLK1+ multipotent cardiovascular progenitors
(MCPs) in NKX2-5 dox-inducible ES cell lines (at day 5). The mean of 6–7 independent experiments is shown.
(E, F) FACS quantification of cTNT + cardiomyocytes (D) and CD31+ endothelial cells (E) at day 8. (G) RT-PCR
quantification of A- and B-set target genes in NKX2-5 WT or Y191C dox-inducible ES cell lines at day 5 in three
independent experiments (24 hr post-induction). Results were normalised to expression in uninduced cells.
p-values were calculated using a t-test (* p < 0.05).
DOI: 10.7554/eLife.06942.017
The following figure supplements are available for figure 3:
Figure supplement 1. WT and mutant NKX2-5 targets identified by DamID in HL-1 cells.
DOI: 10.7554/eLife.06942.018
Figure supplement 2. (A, B) RT-PCR quantification of Nkx2-5 ORF and endogenous Nkx2-5 (specifically detected using
primers in theNkx2-5 3′UTR, which is absent in the inducible construct) in NKX2-5WT/Y191C/ΔHDdox-inducible ES cell lines
at day 6 (WT:ΔHD comparison (A); 48 hr post-dox induction) and day 5 (WT:Y191C comparison (B); 24 hr post-induction).
DOI: 10.7554/eLife.06942.019
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Figure 4. The YRD is essential for interaction between NKX2-5 and NKX2-5ΔHD. (A) Intracellular localisation of V5-tagged NKX2-5ΔHD and HA-tagged
NKX2-5 WT. CV-1 cells were transfected with NKX2-5ΔHD only (top row), NKX2-5 WT only (middle row), or both (bottom row). Solid and dashed lines
highlight the cellular and nuclear boundaries, respectively. (B) Intracellular localisation of transfected V5-tagged NKX2-5 WT (top row) and NKX2-5ΔHD
(bottom row) in HL-1 cells. (C) NKX2-5 homo- and hetero-dimerisation measured by Rluc-PCA in HEK 293T cells. F1 and F2 represent the N- and
Figure 4. continued on next page
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NKX2-5 mutants bind to off-targets
When comparing NKX2-5 WT and mutant peaks, the presence of C sets revealed that mutant
proteins bound a set of unique targets (Figure 2B) that we call ‘off-targets’ potentially reflecting a
gain-of-function. Proportionally, off-target sets were much larger for the more severe NKX2-5ΔHD
than for NKX2-5Y191C (64% of total NKX2-5ΔHD targets [504 peaks]; 37% of NKX2-5Y191C
targets [427 peaks]).
Off-target peaks had specific characteristics. For example, for both NKX2-5ΔHD and Y191C
mutants, C-sets peaks were uni-modal centred at the transcription start site, while A- and B-set
peaks displayed a bimodal distribution around the transcription start site, as for total NKX2-5
WT peaks (Figure 4—figure supplement 3). Testing NKX2-5 mutant off-target genes for over-
representation of GO terms, we found that both off-target sets were enriched in GO terms
chromatin organisation, macromolecular complex assembly, and cell cycle, but not cardiac terms
(Figure 2—figure supplement 3). These results indicated that off-targets are selected via a specific
logic, most likely via interaction with non-cardiac-restricted cofactors.
ETS factor binding sites are enriched in NKX2-5ΔHD off-targets
Using Clover (Frith et al., 2004) to calculate the enrichment of all known TF motifs present in both
C sets (Figure 2—figure supplement 4), we noted that off-target peak sets for NKX2-5ΔHD and Y191C
were not enriched in the NKE, nor in fact DNA-binding sites of virtually all other known cardiac TFs
(Figure 2—figure supplement 4). The most over-represented motif for NKX2-5Y191C was 5′TAAT3′
(Figure 2D), which is similar to the HOX-like site over-represented in NKX2-5 WT targets mentioned
above. Our DamID findings on NKX2-5Y191C are consistent with in vitro data showing that the affinity
of an analogous Drosophila NK2 class HD mutant (vnd/NK2 Y54M) for the NKE is reduced by 10-fold,
while its affinity for the TAAT core was unchanged (Weiler et al., 1998).
For both mutants, off-target peak sets were enriched in other motifs specific to many broadly
expressed TFs that are not known to be part of the cardiac GRN (Figure 2—figure supplement 4).
We focused on the enrichment of TF-binding sites in the C-set of NKX2-5ΔHD, based on the
hypothesis that DNA-binding cofactors of NKX2-5 guide NKX2-5ΔHD to its off-targets. The
motifs for E−26 transformation-specific (ETS) TFs occurred most frequently in NKX2-5ΔHD C-set
peaks (42%) and were significantly enriched compared to random peaks, suggesting that ETS
factors could play a role in guiding NKX2-5ΔHD to its off-targets. ETS factors are broadly
expressed TFs that are activated by phosphorylation downstream of tyrosine kinase receptors.
They are important for extracellular signal-gating in specification of cardiac progenitors in Ciona
(Davidson et al., 2006), eve-positive extra-cardiac progenitors in Drosophila (Halfon et al.,
2000), and for specification of vascular endothelial cells and Gata4 expression in endocardial
cushions in mammals (Schachterle et al., 2011). However, the broader roles of ETS factors in
mammalian cardiogenesis are uncharted.
Figure 4. Continued
C-terminal Rluc fragments, respectively. Data are represented as mean of the normalised luciferase activity ± SEM. Significance was calculated using an
unpaired t-test (**** p < 0.0001). (D) NKX2-5 homo- and hetero-dimerisation measured by processed spectral Fo¨rster Resonance Energy Transfer
(psFRET). Cerulean and Venus represent the donor and acceptor molecules. FRET efficiency is represented as mean ± SEM. p-values were calculated
using a t-test between each pair and its appropriate controls. Significance is as follows: † for p-value < 0.05; ! for p-value < 0.001 ; # for p-value < 0.0001;
values are given if p-value >0.05. (E) Representative psFRET images (false coloured using fire look up table) used in (D). (F) Yeast-two-hybrid assay.
Proteins were fused to Gal4-activation and DNA-binding domains. Positive signs (+) show interaction as growth on selective medium from three
independent experiments (nd = not determined). FRET, Fo¨rster Resonance Energy Transfer.
DOI: 10.7554/eLife.06942.020
The following figure supplements are available for figure 4:
Figure supplement 1. NKX2-5ΔHD interacts with NKX2-5 cardiac cofactors and ETS-factors in vivo.
DOI: 10.7554/eLife.06942.021
Figure supplement 2. NKX2-5 dimerisation with TBX5, TBX20, and GATA4 measured by Rluc-PCA.
DOI: 10.7554/eLife.06942.022
Figure supplement 3. Density of NKX2-5 WT, NKX2-5ΔHD, and NKX2-5Y191C peak sets and of probes relative to the TSS.
DOI: 10.7554/eLife.06942.023
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ELK1/4 and other ETS factors interact with NKX2-5
Many ETS factors are expressed in embryonic hearts (Schachterle et al., 2011), and we selected
ternary complex factors ELK1 and ELK4/SAP-1/TCF-1, whose motifs occurred in 26% of C-set peaks, for
further analysis. We speculated that these ubiquitous TFs are cofactors of NKX2-5 and, in the absence of
compelling cardiac specificity conferred by the HD, guide NKX2-5ΔHD to a subset of off-targets. In the
next set of experiments, we set out to establish this principle.
Antibodies specific for total ELK1 or its phosphorylated form (pELK1) showed that in HL-1 cells ELK1
was mostly cytoplasmic and unphosphorylated, although in a minority of cells ELK1 was phosphorylated
and nuclear, where it co-localised with endogenous NKX2-5 (Figure 5A,B). In CV-1 cells, transfected
ELK1 was also variably partitioned between the nucleus and cytoplasm as in transfected neurons
(Lavaur et al., 2007). When phosphorylated and nuclear, pELK1 guided co-transfected NKX2-5ΔHD
into the nucleus of CV-1 cells. Conversely, when unphosphorylated, it retained co-expressed NKX2-5
WT within cytoplasmic inclusions (Figure 5C; Figure 5—figure supplement 1). These data suggest that
ELKs and NKX2-5 are interacting cofactors.
Using Rluc-PCA in HEK 293 cells, we confirmed that both ELK1 and ELK4 interacted with NKX2-5 WT
and NKX2-5ΔHD, as well as SRF and TBX5 (Figure 5D, Figure 5—figure supplement 2). NKX2-5 WT
also interacted with ETS-family members ELK3, ETS1, ERF, and GABPα (Figure 5—figure supplement 2).
psFRET confirmed the NKX2-5/ELK1 interaction in both the nucleus and cytoplasm in CV-1 cells
(Figure 5E–F), demonstrating that the interaction was independent of ELK1 phosphorylation and
chromatin binding. SRF is a well-described cofactor of both NKX2-5 and ELK1, albeit in different
contexts (Treisman, 1994). SRF is an effector of several signalling pathways and plays a specific role
during early heart formation via its combinatorial action with NKX2-5 and GATA4 on target genes.
To test whether the NKX2-5/ELK1 interaction was mediated by SRF, we utilised Rluc-PCA. The ELK1
B-box mutation Y159A, which disrupts the interaction between ELK1 and SRF (Ling et al., 1998), still
interacted with NKX2-5 (Figure 5D) and, as for ELK1 WT, could induce nuclear translocation of
NKX2-5ΔHD or retain NKX2-5 WT in cytoplasmic inclusions (Figure 5—figure supplement 1). Thus,
the ELK/NKX2-5 interaction does not require SRF.
In the Y2H assay, we confirmed an interaction between ELK1 and both NKX2-5 WT and NKX2-
5ΔHD (Figure 4F). ELK1 did not interact with the HD, and its interaction with NKX2-5 was blocked by
the YRDY−A mutation, demonstrating that the YRD, in addition to being a haemophilic interaction
domain contributing to NKX2-5 homodimerisation, is a protein:protein interface essential for the
interaction between NKX2-5 and ELK1. Our results are consistent with previous data showing that
a tyrosine-rich region within NK2 class homeo-protein NKX3-1 mediates interaction with prostate-
derived ETS factor (Chen and Bieberich, 2005). The data suggest that ETS factors including ELK1/4
are functional cofactors of NKX2-5 WT during cardiogenesis.
Identification of ELK1/4 targets in HL-1 cells
In order to confirm binding of ELK1/4 to NKX2-5ΔHD off-targets, we identified ELK1 and ELK4 target
peaks in HL-1 cells using DamID. For ELK1 and ELK4, we generated robust data for both N- and
C-terminal Dam fusions. All data sets showed low false discovery rates (Figure 1—figure supplement 4)
and significant overlap between N- and C-terminal Dam fusions (p < 0.001), resulting in 1217 and 875
overlapping peaks for ELK1 and ELK4 fusions, respectively (Figure 6A; Supplementary file 1). De novo
motif discovery identified the known DNA-binding site for both ELK1 and ELK4 as the only over-
represented motif (Figure 6B; Supplementary file 1). The overlap between ELK1 and ELK4 peaks (p <
0.001) was high (48% of ELK1 and 67% of ELK4 peaks; Figure 6A).
ELK1/4 peaks could be assigned to 1423 and 1051 unique target genes, respectively. GO analysis
showed highest over-representation of terms cytoskeletal organisation and RNA processing
(Supplementary file 1), suggesting that, overall, ELK1/4 regulate many generic cellular functions.
ELK1/4 target gene median expression was low in heart and highest in mast cells and macrophages
(Figure 6C). In contrast to NKX2-5 WT peaks, ELK1/4 peaks showed unimodal enrichment centred
across the transcription start site (TSS), identical to those of NKX2-5ΔHD off-targets (Figure 6D,S6C).
These data highlight the architectural differences between the majority of NKX2-5 WT peaks and
those bound by ELK1/4 and NKX2-5ΔHD.
Having established a robust target set for ELK1/4, we determined how many peaks within the
NKX2-5ΔHD C-set were actually occupied by ELK1/4 in HL-1 cells. Of the 506 NKX2-5ΔHD C-set
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Figure 5. NKX2-5 WT and NKX2-5ΔHD interact with ELK1/4. (A) Nuclear expression of endogenous NKX2-5 and
pELK1 in HL-1 cells. Scale bar represents 10 μm. (B) Co-localisation of transfected V5-tagged NKX2-5ΔHD and
endogenous total ELK1 in HL-1 cells. Scale bar represents 10 μm. (C) Co-localisation of transfected HA-tagged ELK1
Figure 5. continued on next page
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peaks, 72 (14.2%) were bound by ELK1/4, representing more than half of the 26% of this C-set
predicted by Clover to carry an ELK1/4 binding motif. By comparison, <1% of NKX2-5ΔHD C-set
peaks overlapped with randomly generated peak sets. In the case of NKX2-5Y191C C-set peaks, 6.5%
were bound by ELK1/4. These data provide strong support for our hypothesis that ELK1/4 directs
NKX2-5 mutants to a subset of off-targets.
To explore the significance of ETS co-occupancy for selection of off-targets, we used DamID to
determine the targets of an NKX2-5 mutant carrying tyrosine–alanine (Y-A) substitutions in the YRD
because this mutant does not interact with ELK1/4. Comparisons between NKX2-5YRDY−A and NKX2-5
WT targets revealed robust B and C-set (650 and 380 peaks, respectively; Figure 2B and
Supplementary file 1). However, in the C-set, only 3.2% of peaks were occupied by ELKs. This
lends further support for the notion that NKX2-5ΔHD binds a subset of its off-targets via cofactors
interacting with the YRD. The proportionally large size of the NKX2-5YRDY−A C-set also suggests that
this mutation is comparable in severity to NKX2-5Y191C (Figure 2B), supporting the genetic evidence
(Elliott et al., 2006).
NKX2-5ΔHD is functional on target genes
Dysregulation of C-set genes may contribute to CHD. To test whether NKX2-5 mutants can influence
the expression of their off-targets, we cloned the promoter regions of Rad50 and Snai2, which bind to
NKX2-5ΔHD, NKX2-5Y191C, ELK1, and ELK4, but not to NKX2-5 WT, into a luciferase reporter. In HEK
293 cells, both promoters were stimulated modestly by NKX2-5 WT but repressed by ELK1 or ELK4
(Figure 6E). NKX2-5ΔHD had no activity alone, but significantly enhanced repression by ELK1 or ELK4,
an activity not displayed by NKX2-5 WT. NKX2-5Y191C had a similar activity, albeit weaker. These
data show that NKX2-5ΔHD indirect binding to off-targets can modify gene expression, at least when
over-expressed.
We next tested whether NKX2-5 mutants could alter off-target gene expression in the inducible ES
cell lines described above. For off-targets from the NKX2-5WT:Y191C comparison, NKX2-5 WT
modulated the expression of 6/22 C-set genes tested by > 1.5-fold (Figure 6F), although the effect on
2 of these (Dock4 and Sparc) could be accounted for by NKX2-5 WT binding to a distinct DamID peak,
and consistently, NKX2-5 WT and Y191C had opposite effects on these two genes. Thus, NKX2-5 WT
influenced a minority of NKX2-5Y191C off-targets. NKX2-5Y191C repressed Dock4 and activated 7/22
other C-set genes with 6 of these not regulated by NKX2-5 WT at the >1.5 fold significance threshold.
Other genes showed a similar trend. Thus, NKX2-5Y191C could regulate ≥36% of its off-targets in this
system.
ELK1/4 are embedded within the cardiac GRN
As shown above, ETS motifs were enriched in NKX2-5ΔHD off-targets. They were also present
although not significantly enriched in total NKX2-5 WT targets. Enrichment was also low in previously
reported genome-wide NKX2-5 targets determined using ChIP-seq, but higher in targets of GATA4,
SRF, and TBX5 (He et al., 2011). These and our DamID data suggest that ELK1/4 play a role in the
normal cardiac GRN. To explore this further, we examined the overlap between ELK1/4 and NKX2-5
Figure 5. Continued
and V5-tagged NKX2-5ΔHD or NKX2-5 WT in CV-1 cells. Arrowheads and arrows show cells with cytoplasmic and
nuclear NKX2-5 staining, respectively. (D) Interactions between NKX2-5, NKX2-5ΔHD, or SRF and ELK4, ELK1, or
ELK1Y159A measured by the Rluc-PCA in HEK 293T cells. (E) Interactions between ELK1 and NKX2-5 or NKX2-5ΔHD
measured by psFRET in CV-1 cells. p-values: † <0.05; ! <0.001; values are given if p-value>0.05. (F) Representative
psFRET images used in (E).
DOI: 10.7554/eLife.06942.024
The following figure supplements are available for figure 5:
Figure supplement 1. HA-tagged ELK1 expression (green) induces nuclear translocation of V5-tagged NKX2-5ΔHD
(red) in CV-1 cells.
DOI: 10.7554/eLife.06942.025
Figure supplement 2. (A) Interactions between TBX5 and ELK1/ELK4 measured by the Rluc-PCA in HEK 293T cells
(** p < 0.01; *** p < 0.001; ****p < 0.0001).
DOI: 10.7554/eLife.06942.026
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Figure 6. ELK1 and ELK4 co-occupy NKX2-5ΔHD off-targets in HL-1 cells. (A) Overlapping peaks between ELK1,
ELK4, and SRF as shown by proportional Venn diagram. (B) Top binding motifs discovered de novo with Weeder or
Trawler in ELK1, ELK4, and SRF peaks. The TRANSFAC SRF motif and the ELK1/4 motifs determined by (Wei et al.,
2010) in vitro are shown on the right. (C) Normalised median expression of ELK1, ELK4, and SRF target genes in 91
Figure 6. continued on next page
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WT target genes. Of 1490 NKX2-5 WT target genes, 21% (p-value < 2.2e-16, Fisher exact test) were
also bound by ELK1 or ELK4 (Figure 7A), and in 52% of these (including Nkx2-5, Actc1, Id2, and Id3),
the NKX2-5 and ELK1/ELK4 peaks overlapped. Overlaps between SRF and ELK1 targets, and between
SRF and NKX2-5 targets have been documented previously, although not in the same cell type (Boros
et al., 2009a; He et al., 2011; Schlesinger et al., 2011). To complete our comparisons, we therefore
determined SRF targets in HL-1 cells using DamID.
For SRF, we generated data for both N- and C-terminal Dam fusions. SRF peaks showed low false
discovery rates (Figure 1—figure supplement 4) and significant overlaps between N- and C-terminal
Dam fusions (p < 0.001), resulting in 1214 high-confidence peaks (Figure 6A; Supplementary file 1).
These peaks could be assigned to 1314 unique target genes. De novo motif discovery identified the
known SRF motif (CArG box) as the only over-represented motif (Figure 6B; Supplementary file 1)
and present in 26% of targets, supporting the high specificity of DamID. We note that a previous ChIP
study in HL-1 cells reported SRF targets with only a very small fraction containing the CArG box
(Schlesinger et al., 2011). For SRF target genes, GO analysis showed high over-representation of
cardiac (e.g., heart development) and generic (cytoskeletal organisation and RNA processing) terms
(Supplementary file 1). SRF target median expression was highest in heart and skeletal muscle
(Figure 6C), consistent with its known functions. Like NKX2-5 WT, SRF peaks displayed a bimodal
distribution around the TSS (Figure 6D).
The overlap between ELK1/4 and SRF peaks was low (15 and 22% of ELK1 and ELK4 peaks,
respectively; and 20% of SRF peaks; Figure 6A), consistent with previous ChIP studies in serum-
starved HeLa cells suggesting that most ELK1 targets are not co-bound by SRF (Boros et al., 2009a).
In HL-1 cells, targets co-occupied by ELK1/4 and SRF nonetheless included the Fos gene—the
defining target of ternary SRF-ELK complexes (Treisman, 1994).
Targets bound uniquely by ELK1/4 or SRF showed over-representation of GO terms related to
catabolic and metabolic processes, and as for total ELK1/4 targets, were only modestly expressed in
heart (Figure 7A; Supplementary file 1). In contrast, targets bound by NKX2-5 only, NKX2-5, and
SRF, or NKX2-5, SRF, and ELK1/4 were highly expressed in heart. NKX2-5 unique targets were
enriched in GO terms anion transport and regulation of cell motion, while targets co-bound by NKX2-
5 and SRF were enriched in GO terms related to heart contraction. Co-targets of all 3 factors (NKX2-5,
SRF, ELK1/4) or of NKX2-5 and ELK1/4 were most over-represented in GO terms heart development,
blood vessel morphogenesis, and cytoskeleton organisation. These data show that, overall, ELK1/4,
SRF, and NKX2-5 regulate many generic cellular functions, while NKX2-5 and SRF also have more
executive roles in regulating heart development and contraction. Furthermore, ELK1/4 appear to
control very specific subsets of the cardiac GRN. By integrating the targets of all WT TFs profiled with
those of other cardiac TFs previously published, we found that Elk1/4 were embedded in the
developmental cardiac GRN with many cross and feedback connections (Figure 7B), suggesting that
ELK1/4 play a significant role in normal and disease cardiac GRN logic.
Discussion
Here, we used DamID in HL-1 cells to probe the cardiac GRN by identifying target genes for kernel
TFs NKX2-5 and SRF, and for the MAP kinase signalling-dependent cardiac transcriptional cofactors
ELK1 and ELK4. To begin to understand the mechanism of CHD, we adopted the DamID method and
identified targets of NKX2-5 mutants that mimic those found in CHD. These are the first functional
genomics studies to probe CHD, providing new insights into the structure and function of NKX2-5,
and network regulation in normal heart development and CHD.
Figure 6. Continued
murine cell types, including the heart in red (data collected from BioGPS). (D) Density of ELK1, ELK4, and SRF peaks
and probes relative to the TSS. (E) Normalised Rluc activity in HEK 293 cells. NKX2-5 WT and mutants were co-
transfected with a pGL4.24 luciferase reporter under the control of the Rad50- or Snai2-promoters. p-values < 0.01
calculated relative to control are denoted by **. # shows significant difference (p < 0.01). (F) RT-PCR quantification of
NKX2-5Y191C off-target genes in NKX2-5 WT or Y191C dox-inducible ES cell lines at day 5 (24 hr post-induction).
Results were normalised to expression in uninduced cells. p-values were calculated using a t-test (* p < 0.05).
DOI: 10.7554/eLife.06942.027
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Figure 7. ELK1 and ELK4 are embedded in the cardiac gene regulatory network. (A) Overlapping target genes between NKX2-5, ELK1/ELK4, and SRF
visualised using Cytoscape (spring-embed layout). Cluster size is proportional to gene numbers. For each cluster, rectangles indicate the normalised
median expression of target genes in 91 murine cell types (BioGPS). Cell types are ordered by increasing expression values from left to right. Top 3 over-
represented DAVID Gene Ontology (GO) annotations are indicated for each cluster. (B) Regulatory interactions between Elk1/3/4 and cardiac TFs from
DamID experiments and published data sets (network constructed with BioTapestry).
DOI: 10.7554/eLife.06942.028
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Previous studies comparing DamID and ChIP experiments performed in Drosophila reported ‘a
high degree of overlap’ (Moorman et al., 2006; Negre et al., 2006; Tolhuis et al., 2006; van
Bemmel et al., 2010; Yin et al., 2011). We compared our NKX2-5 peak set with NKX2-5 ChIPseq
peaks generated previously in HL-1 cells (He et al., 2011) and adult hearts (van den Boogaard et al.,
2012), restricting our analyses to genomic regions covered by the promoter microarrays
(Figure 1—figure supplement 9). We found that the overlap between all three data sets was
low—specifically 18% and 6% DamID peak overlap, respectively. This low overlap highlights the
problems of comparing data from different platforms and different laboratories, and warrants deeper
analysis. We note that only DamID was performed with 3–4 replicates per experiment. Furthermore,
de novo motif discovery identified the known high-affinity NKE exclusively within NKX2-5 DamID
peaks. Both of the published studies identified a similar but variant NKE using ChIPseq. Cardiac- and
muscle-related GO terms were more highly enriched in NKX2-5 target genes determined by DamID
compared to published ChIPseq peaks from adult hearts included in Figure 1—figure supplement 9
(van den Boogaard et al., 2012), and no such GO term were detected in data from HL-1 cells (He
et al., 2011). These results provide strong validation for the DamID method.
Our study using DamID confirms for the first time at a genome-wide level in vivo, the prevailing
view that severe mutations in cardiac kernel TF (such as NKX2-5ΔHD, Y191C, and YRDY−A) fail to bind
the majority of WT targets (A sets) even in the presence of normal levels of NKX2-5 WT. Loss-of-
binding of mutant proteins will be associated with alterations in the level of expression of many genes
in the cardiac network through haploinsufficiency, which will be a major contributor to the structural
and functional heart defects found in human CHD patients.
Surprisingly, however, NKX2-5 mutants still recognised a large number of genomic sites and some
of these were normally bound by NKX2-5 WT (B-sets). B-sets included direct and indirect NKX2-5 WT
target genes and were enriched in heart- and muscle-related GO terms. In the ES cell system, NKX2-5
mutant proteins retained WT-like functionality on some B-set genes. We propose that B-sets are
recognised by mutants via dimerisation with cofactors or with NKX2-5 WT. The NKX2-5 HD is
a recognised interface for NKX2-5 homo-dimerisation and interactions with cofactors, such as GATA4,
HAND1, TBX5/20, and MEF2. NKX2-5ΔHD lacks the HD and embedded nuclear localisation domain
and represents a severe mutation that has lost the ability to bind to the majority (81%) of normal
NKX2-5 WT targets (A-set). However, even this severe mutant retained binding to a subset of direct
and indirect NKX2-5 WT targets (B-set). NKX2-5ΔHD binding to B-set peaks could only occur through
heterodimerisation with NKX2-5 WT or cofactors. We have shown using a number of approaches that
NKX2-5ΔHD retained its ability to interact with NKX2-5 WT, GATA4, and TBX5/20, and we identified
the YRD located within the C-terminus of NKX2-5 as a novel interface that collaborates with the HD to
support these interactions. Our characterisation of the YRD as a novel homophilic and heterophilic
interaction domain provides the molecular mechanism that explains dimerisation of NKX2-5ΔHD to
NKX2-5 WT or its cofactors in the absence of the HD. We predict that the HD and YRD act
supportively and synergistically in the assembly of macromolecular TF complexes. The YRD is an
ancient domain that has coevolved with the NK2-class HD and is essential for NKX2-5 function in early
mouse embryogenesis (Elliott et al., 2006). In humans, half of NKX2-5 mutations associated with CHD
are outside of the HD, and three frame-shift mutations located within the YRD have been identified
(Benson et al., 1999; Gutierrez-Roelens et al., 2002; Ikeda et al., 2002).
Both NKX2-5 mutants studied also recognised a large number of targets uniquely (C-set), which we
term off-targets. The relative size of the C-set within the total mutant target set (C-set/B-set ratio)
correlates with the location and predicted severity of NKX2-5 mutations (ΔHD>Y191C≥ YRDY−A), and
thus B-set and C-set size and content may prove to be valuable signatures for understanding the
relationship between genotype, phenotype, and clinical outcomes in CHD. NKX2-5ΔHD off-targets
were associated with GO terms chromatin organisation and cell cycle, and peaks were enriched in the
binding sites for ETS family and many other broadly expressed TFs, attesting to an underlying logic in
their selection. A high percentage of NKX2-5 mutant off-targets (14.2% for NKX2-5ΔHD and 6.5% for
NKX2-5Y191C) were occupied by ELK1/4 in HL-1 cells, compared to <1% when randomly generated
peaks were overlapped. Furthermore, only 3% of C-set peaks of the NKX2-5YRDY−A mutant were
bound by ELK1/4. Although ETS factors have previously been predicted to be involved in heart
development based on motif enrichment in predicted cardiac enhancers in fly and humans (Pham
et al., 2007; Narlikar et al., 2010; Jin et al., 2013), this is the first evidence showing a direct
interaction with cardiac TFs. Studies of the Ciona intestinalis cardiac GRN demonstrated that ETS
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family gene Ets1/2 is activated by FGF/MAP Kinase signalling, which specifies the identity of founder
cells of the cardiac lineage (Davidson et al., 2006). Interestingly, most overrepresented in candidate
Ets1/2 target genesis was the motif 5′ATTA3′, (Davidson et al., 2006;Woznica et al., 2012), which is
similar to the HOX-like motif overrepresented in NKX2-5Y191C off-target peaks in HL-1 cells,
potentially indicating a conserved FGF/MAP Kinase-activated synergy between ETS and HD factors at
the earliest stages of cardiac lineage specification.
ELK1 and ELK4 interacted with NKX2-5 WT and NKX2-5ΔHD through the YRD, and this interaction
was sufficiently strong for pELK1 to transport NKX2-5ΔHD into the nucleus when co-expressed and for
unphosphorylated ELK1 to tether NKX2-5 WT in cytoplasmic inclusions. This interaction provides
a mechanism for how severe NKX2-5 mutants lacking a functional HD can be directed to a sub-set of
off-targets via interaction with broadly expressed TFs. Severe NKX2-5 mutants may be drawn to off-
targets due to the breakdown of compelling cardiac specificity on true targets.
We have also shown that ETS factors ELK1 and ELK4 are normal cofactors of NKX2-5, embedded in
the cardiac GRN kernel. The cardiac GRN kernel is traditionally conceptualised as a set of cardiac-
restricted TFs that are critical for defining organ territories and imposing organ specificity to GRN
logic. However, the cardiac kernel is likely to have evolved in the context of a host of ancient TFs
controlling ubiquitous cellular processes such as metabolism, cell cycle, chromatin dynamics, and
cytoskeleton. Furthermore, it is well known that TFs are amongst the targets of the complex paracrine
signalling pathways that underpin pattern formation, tissue specification, and differentiation in
metazoans. Our genome-wide studies suggest that ELK1/4 interact with, regulate, and are regulated
by, cardiac TFs, and are therefore recursively wired into the cardiac kernel at a high level. Other
studies show that organ-restricted NK-2 class HD TFs collaborate with ETS factors on specific target
genes (Chen and Bieberich, 2005; Lin et al., 2006) or provide signal gating for decisions affecting
lineage fate within developmental fields (Halfon et al., 2000; Hollenhorst et al., 2011). ELK1/4 bind
and potentially regulate a large number of genes in HL-1 cells involved in ubiquitous cellular
processes, most prominently metabolism. However, smaller gene sets, most significantly those
encoding heart developmental and cytoskeletal genes, were co-bound by NKX2-5 and ELKs, SRF and
ELKs, or ELK1/4, NKX2-5, and SRF. One interpretation is that subsets of ELK1/4 targets, potentially
those at critical hubs, have been drawn into the cardiac GRN to exert strategic (signal-gated) and fine
network control over its outputs. Considering the implications of this and related studies more
broadly, network links between cardiac and canonical signal-gated TFs are likely to be much greater
than currently appreciated and generate massive potential for regulatory coding that needs to be
tested in future studies.
Our results may have implications for the mechanism of CHD. While we acknowledge that our
findings are derived from studies in a cell culture system, they compellingly suggest that NKX2-5
mutants, even those lacking DNA-binding ability, can bind to a subset of normal targets and off-
targets, where they could affect transcription either positively or through dominant-negative action.
Importantly, both NKX2-5ΔHD and NKX2-5Y191C retained some functionality on select B- and C-set
targets in vitro, an activity driven by heterodimerisation with cofactors. Our results confirm the
inability of severe mutants to bind most normal targets, and therefore that haploinsufficiency is likely
the dominant component of CHD mechanism. However, we predict that allele-specific dominant-
negative and gain-of-function effects arising from dysregulation of the hundreds of off-targets will
further destabilise the cardiac GRN and could contribute to disease. We have not yet analysed the
expression of off-targets in mouse models or human CHD samples. Defining the targets and off-
targets of a range of human CHD mutations and analysing their expressions in appropriate animal and
human models will be needed to rigorously test the hypothesis.
Materials and methods
Plasmids and cell culture
Plasmids/cloning
Sequences coding for murine TFs used in this study were amplified from HL-1 cell cDNA and cloned
into DamID vectors generated previously (Vogel et al., 2006). The mouse NKX2-5Y191C mutant was
generated by site-directed mutagenesis of the Nkx2-5 cDNA using the following primer and its
reverse complement: TCCAGAACCGTCGCTGCAAGTGCAAGCGACAG. The NKX2-5ΔHD (NKX2-5
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V142_Q199del) was constructed by replacing the HD with 8 glycine residues. Vectors used for
lentivirus production were obtained from Prof D Trono/Addgene: pMLDg/pRRE (12,251), pRSV-Rev
(12,253), and pMD2.G (12,259) (Dull et al., 1998).
Cell lines
The HL-1 cell line was donated by Prof W C Claycomb (Department of Biochemistry and Molecular
Biology, Louisiana State University, New Orleans, LA, USA) (Claycomb et al., 1998). Human
embryonic Kidney 293 FT and Ecr 293 cells were from Invitrogen.
For doxycycline (dox)-inducible mouse ES cell lines, Nkx2-5 WT, Nkx2-5ΔHD, and Nkx2-5Y191, open
reading frames were amplified by PCR from the plasmids described in section ’Plasmids/cloning’,
sequence-verified and cloned in place of Mesp13XFlag in the p2LoxMesp1-3XFlag-IRES-EGFP vector
(Bondue et al., 2008). These constructs were electroporated in A2Lox cells, and stable cell lines were
selected (Bondue et al., 2008).
ES cells were cultured on irradiated mouse embryonic fibroblasts (Bondue et al., 2008, 2011).
Before differentiation, one ES cell passage was performed on gelatine-coated plates to eliminate
remaining fibroblasts. ES cell differentiation was performed in re-aggregated EBs in serum-free
conditions (Kattman et al., 2011b). Briefly, to allow their re-aggregation, ES cells were dissociated
with trypsin and grown in Corning ultra-low adhesion plates at a density of 75,000 cells/ml for 48 hr
without growth factors. After 2 days, the medium was changed and growth factors added (12.5 ng/ml
BMP4, 6 ng/ml Activin, and 5 ng/ml VEGF) for 48 hr. At day 4, EBs were collected and replated on
gelatine-coated plates in a StemPro34-based medium (Life Technologies, Carlsbad, USA),
supplemented with 100 U/ml Penicillin (Life Technologies), 100 μg/ml Streptomycin (Gibco), 2 mM
L-Glutamine, 50 μg/ml ascorbic acid (Sigma-Aldrich, St Louis, USA), 10 ng/ml bFGF, 25 ng/ml FGF10,
5 ng/ml VEGF, and 5 μM IWR1 (Willems et al., 2011; Kattman et al., 2011a). All growth factors were
purchased from R&D, except for IWR1 obtained from Sigma. After replating, medium was replaced at
day 6 and 8 of differentiation. When indicated, dox was added at day 4 at a final concentration of
1,000 ng/ml (Bondue et al., 2008).
Immunofluorescence and imaging
Immunofluorescence on fixed cells was performed as described by (Chapman et al., 2011).
Antibodies used are listed in Supplementary file 2A.
Transactivation experiments in mammalian cells
Transactivation experiments were performed in HEK 293 FT cells (Costa et al., 2011). We used the
following primers for cis-element PCR-amplification from mouse HL-1 cell DNA: ACGCTCCTGACTT
GACTGTTTT and GCAGCGGCCGACTCTTATAG for the Id3 promoter; CCCGAGTCCCTTGGCTAACT
and AACCCCAGCCCTTCCTACTAAC for the Id3 downstream region (DR); ACCCTGCAGGACAT
GAACTCA and TGGGCTAGGAGGCTCTGTAATA for Rad50; and GCGCTACAAAGGGAGGAAGTC
and CATGCAGGAGACTCCATAGGAG for Snai2. All cis-elements were cloned into the pGL4.24
Luciferase reporter vector (Promega, Madison, USA).
Gene expression by real-time-PCR
For gene expression analysis in mouse embryos, total RNA was extracted from dissected hearts
from embryos aged between 12 and 20 somite pairs (E8.5–E9.0) using the Stratagene Absolutely
Nanoprep Kit (Agilent Technologies, Santa Clara, USA). Six hearts for each genotype wild typeNkx2-5+/+,
Nkx2-5LacZ/+ heterozygous, and Nkx2-5LacZ/LacZ (Elliott et al., 2006) were pooled for reverse
transcription into cDNA using Superscript III (Life Technologies) with poly-(dT). Quantitative PCR was
performed with SYBR green (Roche, Basel, Switzerland) and analysed on the Roche LightCycler480.
Levels of gene expression were normalised to Hprt. Primers are listed in Supplementary file 2B.
For gene expression analysis in mouse ES cells, RNA extraction, DNase treatment, and RT-PCR were
performed as previously described (Bondue et al., 2008, 2011). qPCR was performed using Brilliant II
Fast SYBR qPCR Master Mix on a Mx3005P Real-Time PCR system (Agilent). All primers were designed
using Lasergene 7.2 software (DNAStar Inc, Madison, USA) and are listed in Supplementary file 2B.
Gene expression was normalised to Tbp and Actb.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assays (EMSAs) were performed according to (Watanabe et al., 2012).
Protein production was done according to manufacturer’s recommendations using the Promega TnT
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Quick Coupled Transcription/Translation System. Binding reactions were performed in 75 mM NaCl,
10 mM Tris-Cl pH7.5, 1 mM EDTA, 1 mM DTT, 6% Glycerol, and 1 mMMgCl2 on ice for 60 min. We used
the following oligonucleotides and their reverse complements: GGGACCTTTGAAGTGGGGGCCTC for
the Nppa-NKE; GGGCTGCTTCTGGCAGAATGGAG for NF-1 #I; and GGGCCTCTTCTGGCAGGAGG
GAG for NF-1 #II.
Animal experimentation
Animal experimentation was performed with approval of the Garvan Institute/St Vincent’s Hospital
Animal Ethics Committee (Project numbers 10/19 and 10/01).
ChIP experiments
ChIP experiments were performed in HL-1 cells following the Abcam Cross-link Chromatin (X-ChIP)
protocol. Proteins and DNA were cross-linked with 0.75% formaldehyde at room temperature for 10
min. Immunoprecipitation of chromatin complexes was done using Santa Cruz antibodies cat no
sc365207 for NKX2-5 and sc2025 for IgG control. Target gene levels were quantitatively measured by
PCR. Primers were designed to validate DamID peaks and are provided in Supplementary file 2B.
DamID experiments
DamID experiments were performed after modification of published protocols (Vogel et al., 2007).
In brief, HL-1 cells at confluency were transduced with lentiviral vectors allowing undetectable
expression of TF/Dam fusion proteins in the absence of induction. After 40 hr, genomic DNA was
extracted using a Gentra PureGene Cell kit (QIAGEN, Venlo, Netherlands), digested by DpnI at 37˚C
for 6 hr, and amplified by ligation-mediated PCR. PCR products were further fragmented with
DNaseI at 24˚C for 1 min, and labelled and hybridised to Affymetrix mouse 1.0R promoter
microarrays according to manufacturers’ instructions. Three independent DamID experiments were
performed utilising biological triplicates in first two studies and quadruplicates in the third study
(Supplementary file 2C). Peaks can be directly visualised in the UCSC Genome Browser following this
http://genome.ucsc.edu/cgi-bin/hgTracks?db=mm9&type=bed&hgt.customText=ftp://ftp.ncbi.nlm.nih.
gov/geo/series/GSE44nnn/GSE44902/suppl/GSE44902_DamID.bed.gz. Microarray data were deposited
in NCBI’s Gene Expression Omnibus (GSE44902).
Bioinformatics analysis
Array processing and binding loci (peaks) detection
Quality control was first performed using the ‘affy’ and ‘affyPLM’ R packages to assess the distribution
of probe-levels effects via the RLE and PLM methods (Gautier et al., 2004). RB_NS12.CEL was found
to have elevated NUSE (median away from 1) and RLE (median away from 0). RB_AW10.CEL was
found to have elevated RLE (median away from 0) and an artifact identified by pseudoimage
decomposition of the microarray. Log2 transformed microarray sample probe set intensities
normalised via Robust Multichip Average and followed by complete linkage clustering (Pearson
correlation) also identified RB_NS12.CEL as an outlier. RB_AW10.CEL and RB_NS12.CEL were
removed from subsequent analyses. Probe remapping to NCBI Build 37 (mm9) was performed using
the Starr R package (Zacher et al., 2010). Inputs to Starr for remapping were the probe mappings for
the Affymetrix Promoter 1.0R Array and all chromosomes from the NCBI Build 37 (mm9) in Fasta
format downloaded from the UCSC ftp server. Array normalisation and peak identification were
performed using the CisGenome software package version 2.0 (Ji et al., 2008). Arrays were
normalised using the quantile normalisation method implemented in CisGenome. The TileMapv2
algorithm was then used to detect regions that bound at least 8 probes with a moving average
statistic ≥3.5, all other parameters remained default (Ji and Wong, 2005).
Microarrays (.CEL files) and statistical output from CisGenome (.COD files) were deposited in NCBI’s
Gene Expression Omnibus, accession number GSE44902 (Edgar et al., 2002). A bed file of all peak
coordinates called using CisGenome was compiled and customised for input to UCSC genome browser
(mm9) and available for download from NCBI GEO accession number GSE44902 (Bouveret et al.,
2015). Alternatively, these data can be automatically displayed by clicking the link above.
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Gene assignment and binding site locations
Peaks were assigned to genes using GREAT (McLean et al., 2010) with the following parameters:
Species Assembly: Mouse mm9. Background regions: Custom Perl scripts were written to fetch non-
coding regions from 6.5 kb upstream and 2.5 kb downstream of all EnsEMBL genes (API version 66,
mm9) (Flicek et al., 2012) that are covered by probes on the Affymetrix promoter array. Association
rule settings: Basal plus extension, 6.5 kb upstream, 2.5 kb downstream up to 100 kb. Custom Perl
scripts were written to locate the distance of the median position of each peak from the closest
annotated transcription start site (annotations also obtained through the EnsEMBL API). Position
frequencies were plotted using R (http://www.r-project.org/). Peak overlaps were calculated using the
BEDTools package using a default minimum of 1 bp overlap (Quinlan and Hall, 2010). For
comparison with data from (He et al., 2011) and (van den Boogaard et al., 2012), we obtained
NKX2-5 peaks determined by the authors. Gene overlaps were visualised using BioVenn (Hulsen
et al., 2008).
GO analysis
Functional significance of peaks (TF-binding regions) was assessed using GREAT (McLean et al.,
2010). Significantly enriched GO terms were defined as those with p-value ≤ 0.05 and having at least
4 target genes associated with that term. Functional significance of genes (determined from
overlapping annotations) was performed using DAVID version 6.7 (current release January 2010)
(Huang da et al., 2007; Huang da et al., 2009).Background used to identify enriched GO terms with
GREAT was all genes that could be assigned from the probes on the Affymetrix microarrays. The
whole genome was used as background with DAVID.
DNA motif discovery
De novo motif analysis of TF-binding sites was performed using the stand-alone version of Weeder
1.4.2 (Pavesi and Pesole, 2006) and Trawler_standalone (Haudry et al., 2010). Parameters for
runningWeeder were: search mode=small-medium. Parameters for running Trawler_standalone were:
motif_number=200-1000; mlength=6-12; wildcard=23; strand=double; overlap=70-90; occur-
rence=10; other options remained default. Repeat-masked background sequences from 6500 bp
upstream to 3500 bp downstream of each annotated transcription start site were retrieved from
EnsEMBL using custom Perl scripts (API version 66, mm9) (Flicek et al., 2012).
Clover (Frith et al., 2004) was used to find enrichment of known TF-binding motifs in DamID
peaks. The background sequences used were the regions from 6.5 kb upstream to 3.5 kb downstream
of all genes tiled on the Affymetrix Mouse Promoter Tiling Array. Motifs with p-values<0.05 were
deemed significantly over-or under-represented.
Tissue expression analysis
A pre-processed series matrix file containing the expression profiles of 91 mouse cell and tissue
types was downloaded from the NCBI Gene Expression Omnibus (GSE10246). Replicates were
transformed to log2 normalised mean expression (NME), and gene symbols were assigned using
the mouse4302.db library in R. Using the background gene assignments from section ‘GO
Analysis’, 1000 genes were drawn at random, and the median of each tissue/cell expression
profile for these genes was calculated from the NME of all samples. This was repeated 100 times
and the average taken to form a static random background expression profile. For any given set
of input genes, a tissue/cell type expression profile was formed by the ratio of the randomly
generated median expression profiles to the median tissue/cell type expression profile of the
input group of genes.
Gene network reconstruction
BioTapestry (Longabaugh et al., 2009) was used to represent the protein-DNA interactions between
cardiac TFs identified in this study and elsewhere (von Both et al., 2004; Davidson and Erwin, 2006;
Mori et al., 2006; Rojas et al., 2008; Silvestri et al., 2008; Boros et al., 2009b; Holler et al., 2010;
van Bueren et al., 2010; He et al., 2011; Schlesinger et al., 2011; Shen et al., 2011). Gene targets of
NKX2-5, ELK1/4, and SRF obtained from the DamID analysis were visualised with Cytoscape using the
spring embedded layout with default parameters (Killcoyne et al., 2009). Each TF surveyed by DamID
was reanalysed with the spring embedded layout resulting in a surface that scaled proportionally to
the number of genes connected to the TF surveyed.
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paFCS
HL-1 cells were seeded onto Lab-Tek chambers (Thermo Scientific, Waltham, USA) with 5 mg/ml
fibronectin and 20 mg/ml gelatine and transfected with indicated paGFP fusion proteins and histone
2B (H2B)-RFP (to identify nuclei) using Lipofectamine 2000 (Invitrogen), as per manufacturer’s
instructions. Fluorescence correlation spectroscopy (FCS) measurements were performed 48 hr post-
transfection, following photoactivation of the paGFP fusion proteins with 405 nm light, as previously
described (Kaur et al., 2013) using the Zeiss LSM780 laser scanning confocal microscope, with the
avalanche photodiodes of the Confocur 3 module (Zeiss, Jena). The autocorrelation function (ACF)
G(t) for the fluorescent intensity over the 20 s measurement was calculated using the ZEN software
FCS module (Zeiss, Jena, Germany). Mean ACFs (of 7 repetitions) were fitted using the ZEN Software
(Zeiss) using a model that comprised two 3D diffusion terms, one free and one anomalous, and
another term to account for triplet state photophysics (see [Kaur et al., 2013] for further details).
Protein–protein interactions
Split-luciferase protein fragment complementation assay
The Renilla luciferase protein fragment complementation assay (Rluc-PCA) was performed based on
a modified version of the technique described by Stefan et al. (2007). Protein-coding sequences were
cloned into a pcDNA3 expression vector backbone, which was modified to contain either Renilla
luciferase fragment 1 (Rluc8.1, amino acids 1–110) or Renilla luciferase fragment 2 (Rluc8.2 amino
acids 111–312), each followed by a 2×(GGGS) linker, upstream of a Gateway cloning cassette allowing
insertion of the gene of interest. The resulting fusion is under the control of a truncated form of the
CMV promoter (CMVd1), allowing for reduced levels of protein expression (Promega). Transfection
efficiency was normalised by a third vector encoding LacZ, downstream of a CMV promoter (CMV-
LacZ). The day before transfection, 20,000 HEK 293T cells were plated in clear-bottomed, white-
walled 96-well plates in 100 ml DMEM/10% FCS growth media. A master mix for each quadruplicate
was prepared, containing 16 μl Optimem (Life Technologies), 40 ng CMV-LacZ, 180 ng R.luc8.1
Fusion, 180 ng R.luc8.2-Fusion, and 0.8 μl FuGeneHD (Roche). The mix was incubated for 10 min,
and equal amounts of mix added to each well of the quadruplicate. After 24 hr, cells were washed in
PBS and 100 μl of PBS added to each well. A 10 mM solution of Benzyl Coelenterazine in PBS
(Nanolight Technologies, Pinetop, USA) was prepared from a 10 mM stock solution in methanol, and
100 μl was injected into each well by luminometer (FluoStar Optima, BMG Labtech). Readings were
taken for 5 s, 2 s after injection, and again for 5 s 15 min after initial injection of substrate. Following
readings, cells were washed with PBS and ß-galactosidase detected using the Galacto-Star System (Life
Technologies). Renilla luciferase readings were then normalised to levels of ß-galactosidase and the
four replicates averaged. As Glutathione transferase dimerises, fusions to Rluc8.1 and Rluc8.2 were
used as a positive control and were used separately with other proteins of interest as negative controls.
FRET
CV-1 cells were seeded onto coverslips, and upon reaching ∼70% confluency were transfected with
the appropriate plasmids encoding Cerulean- and Venus-TF fusions, following the protocol supplied
with Lipofectamine LTX reagent (Life Technologies). Briefly, for each well of a 6-well plate containing 2
ml of DMEM (minus FBS), 500 μl of Optimem was added to each plasmid mixture and 2.5 μl of Plus
reagent added. This mixture was left to incubate at room temperature for 5 min, before 6.25 μl
Lipofectamine LTX was added to each DNA/Optimem/Plus reagent mixture.
Following 30 min incubation at room temperature, 500 μl of the resulting DNA-lipid complexes were
added drop wise to the appropriate well. Complexes were left on cells for 4–5 hr, before the serum-free
media was replaced with DMEM containing 10% FBS and incubated 16–24 hr. Prior to live imaging, media
were changed to phenol-red free DMEM, and the coverslip was mounted in a POCmini-2 cultivation
system (Zeiss) in DMEMgfp medium (Evrogen, Moscow, Russia) containing 10% FCS on a LSM 7Duo
confocal microscope equipped with a 32-channel spectral detector. 12-bit spectral images were acquired
using a 63× Plan-Apochromat 1.40 oil objective at a spectral resolution of 10 nm, first with 405 nm laser
excitation and then with a 514 nm laser. Donor, raw FRET, and acceptor images were obtained by linear-
unmixing spectral data using newly acquired reference spectra in the Zen 2009 software (Zeiss). Images
with average pixel values above 300 and below 2900 were processed through the psFRET algorithm to
remove donor spectral bleed-through from the raw FRET signal (Chen et al., 2007).
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Yeast two-hybrid assay
Protein-coding sequences were cloned into pGADT7 AD or pGBKT7 DBD expression vector
backbones (Clontech, Mountain View, USA), which were modified to contain a Gateway cloning
cassette. pGADT7-AD and pGBKT7-DBD fusions were co-transformed into chemical competent S.
cerevisiae strain AH109 (Clontech). Double transformants were selected for growth on -Leu/-Trp
selection plates, before being selected for interaction on -Ade/-His/-Leu/-Trp selection plates.
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